Confidential Marketplace · A.N.D.A. Divestment

Turn dormant ANDAs into significant cash.

ANDA Exchange is the dedicated marketplace for approved, discontinued, and unused Abbreviated New Drug Applications — privately connecting sellers with a vetted network of 5,000+ prospective buyers.

Selling instead? List your ANDA confidentially →

5,000+
Prospective buyers in network
$0
Upfront cost — success-fee only
100%
Confidential until you approve
End‑to‑end
Valuation · negotiation · diligence
What Is ANDA Exchange

A dormant application on the FDA's discontinued list is still a valuable asset.

Thousands of approved ANDAs sit unused on company shelves and the FDA discontinued list. We exist to match those assets with manufacturers actively looking to enter the market — quickly, discreetly, and at fair value.

Unlock trapped value

Discontinued and unused ANDAs generate no revenue but still carry real market value. We convert that dead weight on your books into cash.

A buyer network, ready

We've spent years building relationships with 5,000+ generic manufacturers and marketers. Your asset reaches the right desks immediately.

Discreet by design

Listings are anonymized. Your company's identity is never revealed to a prospect until you've approved them under a confidentiality agreement.

For Sellers

You hold the ANDA. We find the buyer.

  • Promote approved, discontinued or unused ANDAs to a curated buyer pool
  • Independent market valuation so you price with confidence
  • We manage negotiation and the buyer's due diligence end-to-end
  • No upfront fees — we earn only a small percentage of your proceeds
List your ANDA
For Buyers

Enter the market in months, not years.

  • Acquire an already-approved application instead of filing a new ANDA
  • Skip the multi-year FDA review queue and launch faster
  • Pre-screened opportunities matched to your therapeutic focus
  • Full diligence support from a team that knows the dossiers
Explore acquisitions
How It Works

From shelf to sale in four steps.

01

List confidentially

Tell us which ANDAs you hold. We build an anonymized listing — no company name attached.

02

Value & promote

We establish a market valuation and discreetly promote the asset to matched buyers in our network.

03

Negotiate & diligence

We manage offers, broker the negotiation, and support the buyer's due diligence on the dossier.

04

Close & get paid

The deal closes between you and the buyer. We collect only a small percentage of your proceeds.

Current Opportunities

A look at our available applications.

View all 51 listings
Under Review Cardiovascular

Sacubitril & Valsartan

Tablet · 24/26, 49/51, 97/103 mg

View in marketplace
Why ANDA Exchange

Specialists in a market most brokers don't understand.

Divesting an ANDA isn't a generic M&A transaction. It demands fluency in FDA dossiers, generic market dynamics, and the handful of companies who'll actually pay for a given application. That's the only thing we do.

Sector-only focus

Exclusively ANDAs — not a sideline of a broader brokerage.

Aligned incentives

We're paid when you are. No retainers, no listing fees.

Real relationships

Buyers we've worked with for years, not a cold database.

Discretion first

Your identity stays private until an NDA is in place.

What we place

The applications that move through ANDA Exchange

  • Approved ANDAs that are unmarketed or no longer core to the portfolio
  • Discontinued products still carried on FDA records
  • Tentative approvals and applications still under review
  • Single assets or full generic portfolios

Confidential valuation, buyer matching, and diligence support — handled end to end, under NDA.

Stay in the loop

Subscribe to our newsletter

New ANDA opportunities, market notes, and divestment insight — sent occasionally, never spam.

Have ANDAs gathering dust? Let's value them.

A confidential, no-obligation conversation is the first step. Tell us what you hold and we'll tell you what it's worth.

Our Network

Part of a connected group.

ANDA Exchange is one of four specialist firms working across the pharmaceutical lifecycle.